SANTA CLARA, Calif., Dec. 2, 2010 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board : NWCI ) a cardiovascular diagnostic solutions developer, announced today that Dr. Dorin Panescu, Chief Technical Officer and Vice President Research and Development, has been named an IEEE Fellow, effective January 1, 2011.
The IEEE Grade of Fellow is conferred by the IEEE Board of Directors upon a person with an outstanding record of accomplishments in any of the IEEE fields of interest. The total number selected in any one year cannot exceed 0.1% of the total voting membership. IEEE Fellow is the highest grade of membership and is recognized by the technical community as a prestigious honor and an important career achievement. 321 individuals have been elevated to IEEE Fellow for 2011.
Dr. Panescu is being recognized for "for contributions to medical devices for cardiac applications." Throughout his career, Dr. Panescu has contributed to the development of radiofrequency cardiac ablation and mapping systems, of implantable pacemakers and defibrillators and, while at NewCardio, of a novel 3-D ECG platform intended for chronic and acute patient care and for cardiac safety testing during drug development. Patients affected by conditions such as supraventricular tachycardias, atrial fibrillation, ventricular tachyarrhythmias, bradycardias, or by ischemic conditions can benefit from treatment with devices or systems such as those contributed to, at least in part, by Dr. Panescu.
Dr. Panescu is an inventor or co-inventor on over 130 issued U.S. patents, many more additional international patents, and author or co-author on over 100 technical publications – book chapters, peer-reviewed journal articles and conference abstracts – related to cardiac pacing, defibrillation, radiofrequency ablation and imaging. He is also the 2009 recipient of the prestigious Professional Career Achievement Award from the IEEE Engineering in Medicine and Biology Society.
Dr. Panescu commented, "I am honored and gratified to be named an IEEE Fellow, and I look forward to continuing my work in the future, as NewCardio progresses toward adding value to each and every ECG performed around the world."
Vincent Renz, NewCardio's President and Chief Executive Officer, added, "We congratulate Dorin on this impressive milestone achievement. NewCardio has been committed to building a world-class management team, comprised of industry leaders in science, technology and operations, to ensure excellence in the design, development and support of our 3-D ECG platform solutions. The naming of Dorin as an IEEE Fellow – a rare and prestigious designation – demonstrates the depth and quality of the team we have created."
The IEEE is the world's leading professional association for advancing technology for humanity. Through its 385,000 members in 160 countries, the association is a leading authority on a wide variety of areas ranging from aerospace systems, computers and telecommunications to biomedical engineering, electric power and consumer electronics.
Dedicated to the advancement of technology, the IEEE publishes 30 percent of the world's literature in the electrical and electronics engineering and computer science fields, and has developed more than 900 active industry standards. The association also sponsors or co-sponsors nearly 400 international technical conferences each year. If you would like to learn more about IEEE or the IEEE Fellow Program, please visit www.ieee.org.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
SOURCE NewCardio, Inc.